| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CAY10594 | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.0071 | 0.9 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | 0.0064 | 0.9 |
| mRNA | ML258 | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | 0.0079 | 0.9 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.0083 | 0.9 |
| mRNA | MP470 | GDSC1000 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | AT13387 | CTRPv2 | pan-cancer | AAC | 0.0071 | 0.9 |
| mRNA | selumetinib:PLX-4032 (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |